
Bio-Techne (TECH) Stock Forecast & Price Target
Bio-Techne (TECH) Analyst Ratings
Bulls say
Bio-Techne is a global leader in the life sciences market, with a focus on providing high-quality reagents, instruments, and other products to support research and diagnostics. Its diverse product portfolio and strong presence in key markets, such as the US and Europe, provide a solid foundation for future growth. The recent divestment of its Exosome Diagnostics business and brand consolidation efforts demonstrate proactive self-help initiatives that are driving margin expansion and position the company for a rebound in demand. Its strong position in the emerging cell therapy market and the pending acquisition of Wilson Wolf indicate potential for even greater growth. While there are some risks, such as potential for market share loss to larger competitors and delay in end market recovery, Bio-Techne's strong management team and ongoing focus on self-improvement make it an attractive investment opportunity with a positive outlook.
Bears say
Bio-Techne is currently facing material sustainability challenges in product quality and safety, environmental impact, and human capital management, as well as lacking validated science-based emissions targets. Additionally, the upcoming acquisition of Wilson Wolf, a high growth cell therapy tools company, could bring about transformative opportunities for Bio-Techne. However, there are downside risks, including potential delays in industry demand recovery, loss of market share to competitors, and disappointing progress in the cell therapy market. Furthermore, the company has a mixed track record in M&A and could face potential challenges related to the rise of AI in the life sciences industry.
This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.
Bio-Techne (TECH) Analyst Forecast & Price Prediction
Start investing in Bio-Techne (TECH)
Order type
Buy in
Order amount
Est. shares
0 shares